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Abstract The aim of this study is to compare effectiveness
and safety of Infliximab (INF), Etanercept (ETN), and
Adalimumab (ADA) in patients with psoriatic arthritis
(PsA) with inadequate response to a previous disease-
modifying antirheumatic drug (DMARD). One hundred
consecutive PsA patients with inadequate response to a
previous DMARD entered this study. Clinical and labora-
tory assessment at baseline (T0) and 12 (T12) months were
performed and included physical examination, vital signs,
global Psoriasis Area and Severity Index (PASI; extension
of psoriasis), tender joints count (TJC), swollen joint count,
health assessment questionnaire (HAQ; questionnaire for
measuring disability), and monitoring of adverse events
(AEs). After enrolment, all patients were randomly given
INF 5 mg/Kg every 6–8 weeks, ETN 50 mg weekly, or
ADA 40 mg every other week. Baseline therapy with
DMARD remained unchanged. Effectiveness was defined
as percentage of ACR20 responders and as clinical remission
and/or minimal disease activity at 12 months treatment. INF,
ETN, and ADA all effectively controlled signs and symptoms
of PsA. All variables tested showed at T12 for each treatment
a significant variation from the baseline value. In particular,
patients on INF and ADA showed the greatest improvement
in terms of PASI, while patients on ETN showed the greatest
improvement on TJC and HAQ. ACR response rates were
72% of patients on ETN, 70% of those on ADA, and 75% of
those patients on INF. Occurrence of AEs was reported in
15% of the cases. Only two AEs in patients on INF were
considered drug related, pneumonitis and thrombocytopenia,
respectively. All tumor necrosis factor-α blockers significant-
ly controlled signs and symptoms of PsA. An increased
knowledge of the different profiles of these agents may help
in optimizing their use.
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Introduction
Psoriatic arthritis (PsA) is a spondyloarthropathy occurring in
patients with skin and/or nail psoriasis [1]. Recent evidences
underline its severity, which leads to progressive joint
damage with radiographic changes, usually appearing within
2 years of clinical onset [2]. Therefore, appropriate therapy
has to be promptly started in order to control symptoms,
inflammation, and to prevent progression of articular damage.
Traditionally, treatment for the established form of
arthritis primarily includes nonsteroidal anti-inflammatory
drugs (NSAIDs) and, in addition, disease-modifying anti-
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rheumatic drugs (DMARDs). NSAIDs are used with the
sole aim of controlling joint symptoms, not showing any
effect on the progression of structural damage. Traditional
DMARDs are employed with the aim of restraining inflam-
matory process, but their usefulness still remains controversial.
In fact, a recent meta-analysis of therapies of PsA found
methotrexate, sulfasalazine, and leflunomide to be effective,
but their benefits appear modest at best [3].
Tumor necrosis factor (TNF)-α is a pro-inflammatory
cytokine that acts a complex role in the pathogenesis of
psoriasis and PsA.
The recent use of TNF-α blockers in the treatment of
psoriasis and PsA has generated an increased interest in this
field. TNF-α blockers have efficacy in providing a clinical
response and in preventing the progression of articular
damage. Their use is expensive, and also the Italian Society
of Rheumatology provided clinical suggestions to discipline
this therapy in patients with recalcitrant PsA [4].
Therefore, this study was conducted with the aim of
comparing the effectiveness and the safety of three different
TNF-α blockers in a cohort of Italian patients with established
PsA who experienced an inadequate response to a previous
DMARD therapy.
Study design
The study was designed as longitudinal, and it was carried
out as single-center, enrolling consecutive patients affected
by PsA, attending their follow-up visit at the outpatient
clinic for PsA patients, regardless of the disease duration.
PsA was based on the CASPAR classification criteria [5].
Inclusion criteria were age >18 years and an inadequate
response to a previous DMARDs therapy.
The study protocol considered a recruitment period from
January 2005 until December 2007. During that period of
time, 1,240 patients with PsA were consecutively seen at
our outpatient clinic; out of them, 100 were considered
active and eligible for the present study.
The exclusion criteria were previous usage of anti-TNF-
α inhibitors; the usage of DMARDs other than sulfasalazine,
methotrexate, azathioprine, and leflunomide within 4 weeks
of enrolment; the usage of more than 10 mg prednisone daily;
and variation of dosage of NSAIDs or prednisone within
2 weeks of enrolment. None of the 100 PsA patients showed
any of the exclusion criteria. All patients treated with
DMARDs were on stable dosage for at least 6 months.
All patients gave their written informed consent, and the
study protocol was approved by the local Ethical Committee.
Patients and methods
One hundred consecutive patients with active PsA, routinely
attending the Psoriatic Arthritis Clinic at the University
Federico II (60 females and 40 males, mean age 48.5±
12.5 years; median duration of disease 80 months, range
20–140) who experienced an inadequate response to a
previous DMARD therapy (Table 1) entered this study.
In patients eligible for therapy with TNF-α blockers, we
performed tuberculin skin test and interferon gamma
release assay tests to screen latent tubercular infection.
After the screening, all patients were randomly given
Infliximab (INF) at dosage of 5 mg/Kg every 6–8 weeks
(increasing or decreasing the dosage when warranted),
Etanercept (ETN) 25 mg twice weekly, and Adalimumab
(ADA) 40 mg every other week.
Disease activity
The patients were followed up every 3 months for a total of
1 year. Clinical and laboratory assessment was carried out
at baseline (T0) and at every 3 months (T3, T6, and T9) and
at 12 months (T12), including physical examination, vital
signs, global Psoriasis Area and Severity Index (PASI;
measure of the extension of psoriasis), tender joints count
(TJC; 68 tender joints), swollen joint count (SJC; 66
swollen joints), and health assessment questionnaire
(HAQ) score (measure of function and disability).
Data were collected at inclusion and at each visit, and in
this paper, we report on the effectiveness and safety of
Table 1 Demographic, baseline, clinical, and therapeutic characteristics of patients
Overall (n=100) Etanercept (n=36) Adalimumab (n=34) Infliximab (n=30) p
Gender (male) 40 (40) 15 (42) 14 (41) 11 (37) 0.91
Age (years) 48.5±12.5 49.3±13.4 47.5±11.5 48.5±12.9 0.84
PASI 19 (18.2) 26 (18.5) 18 (16.5) 15 (14.8) 0.08
HAQ 1.2 (0.4) 1.2 (0.4) 1.2 (0.3) 1.5 (0.5) 0.03
Tender joints 12 (6) 13 (5) 13 (7) 12 (4.8) 0.41
Swollen joints 4 (2) 4 (3.2) 5 (3.8) 3 (3) <0.01
Values are mean±SD, median (interquartile range) or absolute frequency (percentage)
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therapy with TNF-α blockers based on the variation
between T0 and T12 on the various endpoints. ACR20
responses rates were taken into account to measure the
effectiveness of the three medications. However, we
calculated also the clinical remission that was defined by
the physician as absence of swollen and tender joints, as
previously defined [6], while minimal disease activity
(MDA) was defined by the physicians as absence of
swollen joints, no more than two tender joints associated
to a HAQ score <0.5, at 12 months observation.
Statistical analysis
Age is expressed as mean±SD, while other continuous
variables are expressed as median (interquartile range), and
categorical variables are expressed as absolute frequency
(percentage).
Differences between treatment groups on baseline
measures and after 1-year follow-up were tested using
analysis of variance, Kruskal–Wallis tests, or the χ2 tests, as
appropriate.
The analyses were made using R statistical software
(R Development Core Team, 2008).
Results
Demographic and clinical characteristics of the studied
cohort measured at baseline and after 1 year are tabulated
in Tables 1 and 2, respectively. Fifty-one patients were on
combination methotrexate and biologic agent (ETN 40%,
INF 90%, and ADA 30%), and 20% of them showed a
disease duration ≤24 months. Patients treated with INF
tended to have higher HAQ values (p=0.03) and lower
number of swollen joints (p<0.01) than the patients treated
with ADA and ETN at baseline. On the other hand, the
patients on ETN had the highest PASI score at baseline, but
no significant differences were found with the other two
biologic agents.
The distributions of the endpoint variables at baseline and
at 1 year for the three treatment groups are depicted in Fig. 1.
In particular, all endpoints at 1-year observation were
significantly different compared to those at baseline visit.
ETN, INF, and ADA effectively controlled signs and
symptoms of patients with PsA included in this study. In
fact, all variables tested showed at T12, for each treatment,
a significant variation from the baseline value T0. However,
ACR response rates were 72% of patients on ETN, 70% of
those on ADA, and 75% of those patients on INF.
A statistical significant difference among the drugs at
1 year was found in terms of PASI by means of univariate
analysis (p<0.01). In particular, patients treated with ADA
and INF showed the greatest improvement of the extension
of the psoriatic rash when compared to those treated with
ETN (p<0.01 and p<0.001).
When compared to ADA and IFN, patients treated
with ETN showed better improvement of TJC (p<0.018
and p<0.012, respectively), while no significant differences
for SJC were found among the three groups of patients
included in this study.
Finally, patients taking ETN showed better decrease of
HAQ when compared with patients taking ADA (p<0.002).
No patients reached the remission as previously defined,
while they reached the MDA as a group. In particular,
26 patients on ETN reached an MDA status, as defined, and
16 on ADA, with a cumulative number on this latter group
not satisfying the complete definition.
Adverse events
Adverse events (AEs) were recorded in 15% of cases.
Patients under ADA when compared to those under INF or
ETN showed the lowest rate of events (INF 23%, ETN
17%, and ADA 6%; p<0.001). No cases of tuberculosis or
demyelinating disease were reported during this study. The
majority of AEs were mild to moderate in all groups. Only
two serious AEs occurring in patients under INF were
considered drug related and consisted of pneumonitis and
thrombocytopenia. Both were resolved with treatment
withdrawal and with the appropriate therapy.
Discussion
Recent evidence demonstrated that PsA is a relatively
frequent condition which shows a profound impact on the
Table 2 Clinical and therapeutic characteristics of patients after 1 year
Overall (n=100) Etanercept (n=36) Adalimumab (n=34) Infliximab (n=30) p
PASI 0.6 (2) 2 (4.4) 0.1 (1.9) 0 (1) <0.01
HAQ 0.1 (0.1) 0.1 (0) 0.1 (0.2) 0.1 (0) 0.60
Tender joints 1 (1) 1 (1) 1 (2) 1 (1.8) 0.12
Swollen joints 0 (1) 0 (1) 0.5 (1) 1 (1) 0.23
Values are median (interquartile range)
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lives of patients. In fact, it develops in up to one third of the
patients with psoriasis, and articular inflammation frequently
leads to a stable structural damage [7], even if it is often still
difficult to assess the real impact of the disease. In fact, it has
been noted that patients with PsA are less tender than those
with rheumatoid arthritis [8].
Moreover, traditional DMARDs used in PSA have not
demonstrable consistent efficacy in clinical practice [9].
Our recent experience outlines controversial results with
MTX at full dosage also in patients with PsA in early
clinical stages [10]. Finally, we do not have reliable tools
that may predict the onset of arthritis and its clinical
outcome.
In the last 20 years, the potentially devastating joint
destruction of PsA has been clearly evidenced, and the need
for a rapid detection and a quick therapeutic intervention
has become mandatory in this condition as well.
The recent introduction of TNF-α blockers in the
therapy of PSA patients developed a great interest because
these drugs showed their ability to control symptoms and
signs of articular inflammation and to prevent radiographic
progression of structural damage.
The results of this study confirmed that all TNF-α
blockers employed improved signs of articular and cutaneous
involvement and ameliorating the function and quality of life
of patients treated as previously described [11]. Our study,
based on clinical practice and aimed to assess the effective-
ness of these biologic agents, seems to show some therapeutic
peculiarities of the three drugs used. In fact, ETN seems to be
more effective on the articular involvement and function,
while ADA seems to be more effective on the cutaneous
involvement, and this is in keeping with the literature [12–14].
Indeed, the patients on ETN had the highest level of PASI at
baseline, and the dosage of 50 mg weekly is recommended
for joint disease and not for skin involvement, and our group
of patients showed a level of PASI quite unusual for a
rheumatological clinic because our center represents the only
tertiary center for the region.
Therefore, the results from this study could be inter-
preted as the three biologic agents are an effective and safe
treatment for PsA patients, but with some differences that
should be taken into account when the treatment is tailored
based on the predominant clinical feature of the disease at
the time of the starting therapy. However, similar results
were already obtained from randomized controlled trials
and in observational studies [12, 15], but not in a “head-to-
head” study based on real clinical practice. The MDA
status, defined by us as a predominant improvement of
articular manifestations and function, was reached from all
three biologic agents as a group and with some differences
among the three TNF-α blockers.
This definition is, in some ways, keeping with that
obtained by the GRAPPA group a few months ago from a
survey among 60 experts in PsA [16].
Moreover, all the three biologic agents showed a good
safety profile, and all patients carried out the treatment.
Fig. 1 Box-plots of health assessment questionnaire, Psoriasis Area and Severity Index, tender joints count, and swollen joint count for the three
treatment groups, Etanercept (E), Adalimumab (A), and Infliximab (I), measured at baseline (0) and after 1 year (12)
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The discovery of anti-TNF-α agents that specifically
block a crucial molecule implicated in the inflammatory
cascade leading to PsA represents a significant advance-
ment in our ability to control disease activity and to inhibit
the progression toward a structural damage. The rapid
improvement of skin rash and of tenderness and swelling of
joints and/or entheses has allowed patients to regain a
relatively normal life. The better knowledge in clinical
practice of TNF-α blockers therapeutic ability could permit
a use that optimizes their peculiarities at most. The results
of this study may support this hypothesis.
Disclosures None.
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